Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA Inc. reported that it has entered into new non-exclusive distribution agreements with Patterson for the distribution of its dental equipment in the United States. The company disclosed this development through a current report and attached a press release as Exhibit 99.1 describing the arrangements. The disclosure is made under Regulation FD and is treated as information that is furnished rather than filed under the securities laws, which limits how it is incorporated into other company reports.
DENTSPLY SIRONA Inc. director Janet S. Vergis reported an automatic increase in her equity holdings through dividend equivalents on restricted stock units (RSUs). On January 9, 2026, she was credited with 200.899 shares of common stock at a price of $0, recorded as an acquisition under code A.
These shares represent dividends on existing RSUs, paid in the form of additional RSUs that follow the same vesting schedule as the underlying awards. Each RSU converts into one share of common stock. Following this transaction, Vergis directly beneficially owns 44,501.066 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Janet S. Vergis reported an automatic increase in her equity holdings through dividend equivalents on restricted stock units (RSUs). On January 9, 2026, she was credited with 200.899 shares of common stock at a price of $0, recorded as an acquisition under code A.
These shares represent dividends on existing RSUs, paid in the form of additional RSUs that follow the same vesting schedule as the underlying awards. Each RSU converts into one share of common stock. Following this transaction, Vergis directly beneficially owns 44,501.066 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Leslie F. Varon reported an acquisition of company equity tied to existing restricted stock units (RSUs). On 01/09/2026, Varon received 198.141 shares of common stock at a price of $0, reflecting dividends on previously granted RSUs that were paid in the form of additional RSUs. These dividend-equivalent RSUs carry the same vesting terms as the underlying awards and will vest at the same time. After this transaction, Varon directly beneficially owned 57,541.066 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Leslie F. Varon reported an acquisition of company equity tied to existing restricted stock units (RSUs). On 01/09/2026, Varon received 198.141 shares of common stock at a price of $0, reflecting dividends on previously granted RSUs that were paid in the form of additional RSUs. These dividend-equivalent RSUs carry the same vesting terms as the underlying awards and will vest at the same time. After this transaction, Varon directly beneficially owned 57,541.066 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. executive Daniel T. Scavilla, the company’s President, CEO and a director, reported acquiring additional common stock through equity compensation. On January 9, 2026, he received 245.816 shares of common stock at $0 per share, recorded as an acquisition. After this transaction, he directly beneficially owned 17,944.546 common shares.
According to the footnote, these shares represent dividends on restricted stock units (RSUs) paid in the form of additional RSUs, which follow the same vesting schedule as the underlying awards. The dividend RSUs vest at the same time as the related RSUs, and each RSU will convert into one share of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. executive Daniel T. Scavilla, the company’s President, CEO and a director, reported acquiring additional common stock through equity compensation. On January 9, 2026, he received 245.816 shares of common stock at $0 per share, recorded as an acquisition. After this transaction, he directly beneficially owned 17,944.546 common shares.
According to the footnote, these shares represent dividends on restricted stock units (RSUs) paid in the form of additional RSUs, which follow the same vesting schedule as the underlying awards. The dividend RSUs vest at the same time as the related RSUs, and each RSU will convert into one share of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky reported routine equity awards tied to his board service. On January 9, 2026, he acquired 395.158 shares of common stock at $0, representing dividends paid on his existing restricted stock units (RSUs). These dividend RSUs follow the same vesting schedule as the underlying RSUs and each RSU converts into one share of common stock. After this transaction, he beneficially owned 28,846.534 common shares directly.
On the same date, he also acquired 153.7009 phantom stock units under the directors' deferred compensation program at an assigned value of $12.22 per unit, increasing his directly held phantom stock balance to 14,535.2138 units. Each phantom stock unit is economically equivalent to one share of common stock and becomes payable in common stock when his service as a director ends.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky reported routine equity awards tied to his board service. On January 9, 2026, he acquired 395.158 shares of common stock at $0, representing dividends paid on his existing restricted stock units (RSUs). These dividend RSUs follow the same vesting schedule as the underlying RSUs and each RSU converts into one share of common stock. After this transaction, he beneficially owned 28,846.534 common shares directly.
On the same date, he also acquired 153.7009 phantom stock units under the directors' deferred compensation program at an assigned value of $12.22 per unit, increasing his directly held phantom stock balance to 14,535.2138 units. Each phantom stock unit is economically equivalent to one share of common stock and becomes payable in common stock when his service as a director ends.
DENTSPLY SIRONA Inc. director Gregory T. Lucier reported an automatic award of additional common stock tied to existing restricted stock units. On 01/09/2026, an entity described as a family partnership associated with him received 341.114 shares of common stock at a price of $0, reflecting dividends on his restricted stock units that were paid in the form of additional RSUs.
After this transaction, the family partnership held 24,901.284 common shares indirectly. Separately, an IRA associated with Gregory Lucier held 21,000 common shares indirectly, while his direct common stock holdings were reported as zero. The footnote explains that these dividend RSUs follow the same vesting schedule as the underlying RSU awards and each RSU converts into one share of common stock.
DENTSPLY SIRONA Inc. director Gregory T. Lucier reported an automatic award of additional common stock tied to existing restricted stock units. On 01/09/2026, an entity described as a family partnership associated with him received 341.114 shares of common stock at a price of $0, reflecting dividends on his restricted stock units that were paid in the form of additional RSUs.
After this transaction, the family partnership held 24,901.284 common shares indirectly. Separately, an IRA associated with Gregory Lucier held 21,000 common shares indirectly, while his direct common stock holdings were reported as zero. The footnote explains that these dividend RSUs follow the same vesting schedule as the underlying RSU awards and each RSU converts into one share of common stock.
DENTSPLY SIRONA Inc. senior executive Robert Anthony Johnson, SVP and Chief Supply Chain Officer, reported routine equity compensation grants. On January 9, 2026, he acquired 641.625 shares of common stock at a price of $0, representing dividends on existing restricted stock units paid in the form of additional RSUs that vest on the same schedule as the underlying awards. After this, he beneficially owned 116,313.146 shares of common stock directly.
On the same date, he was credited with 40.22 phantom stock units under the Supplemental Executive Retirement Plan at a reference price of $12.22 per unit, bringing his total phantom stock balance to 3,113.1526 units. Each RSU and each phantom stock unit is economically equivalent to one share of common stock, with phantom stock payable in common stock upon his termination of employment.
DENTSPLY SIRONA Inc. senior executive Robert Anthony Johnson, SVP and Chief Supply Chain Officer, reported routine equity compensation grants. On January 9, 2026, he acquired 641.625 shares of common stock at a price of $0, representing dividends on existing restricted stock units paid in the form of additional RSUs that vest on the same schedule as the underlying awards. After this, he beneficially owned 116,313.146 shares of common stock directly.
On the same date, he was credited with 40.22 phantom stock units under the Supplemental Executive Retirement Plan at a reference price of $12.22 per unit, bringing his total phantom stock balance to 3,113.1526 units. Each RSU and each phantom stock unit is economically equivalent to one share of common stock, with phantom stock payable in common stock upon his termination of employment.
DENTSPLY SIRONA Inc. director Clyde Hosein reported an automatic stock acquisition tied to his existing equity awards. On 01/09/2026, he received 355.0455 shares of common stock at a price of $0, described as dividends on restricted stock units (RSUs) that are paid in the form of additional RSUs.
The footnote explains that these dividend RSUs carry the same vesting terms as the original RSU awards and will vest at the same time as the underlying grants, with each RSU converting into one share of common stock. Following this transaction, Hosein directly beneficially owned 41,252.522 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Clyde Hosein reported an automatic stock acquisition tied to his existing equity awards. On 01/09/2026, he received 355.0455 shares of common stock at a price of $0, described as dividends on restricted stock units (RSUs) that are paid in the form of additional RSUs.
The footnote explains that these dividend RSUs carry the same vesting terms as the original RSU awards and will vest at the same time as the underlying grants, with each RSU converting into one share of common stock. Following this transaction, Hosein directly beneficially owned 41,252.522 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Betsy D. Holden reported an automatic share acquisition tied to her existing equity awards. On January 9, 2026, she acquired 710.956 shares of common stock at a price of $0, reflecting dividends on her restricted stock units (RSUs) that were paid in the form of additional RSUs. These dividend RSUs carry the same vesting terms as the underlying awards, and each RSU converts into one share of common stock. Following this transaction, Holden beneficially owned 54,613.852 shares of DENTSPLY SIRONA common stock in direct ownership.
DENTSPLY SIRONA Inc. director Betsy D. Holden reported an automatic share acquisition tied to her existing equity awards. On January 9, 2026, she acquired 710.956 shares of common stock at a price of $0, reflecting dividends on her restricted stock units (RSUs) that were paid in the form of additional RSUs. These dividend RSUs carry the same vesting terms as the underlying awards, and each RSU converts into one share of common stock. Following this transaction, Holden beneficially owned 54,613.852 shares of DENTSPLY SIRONA common stock in direct ownership.
DENTSPLY SIRONA Inc. director Brian T. Gladden reported receiving additional equity-linked compensation. On 01/09/2026, he acquired 314.959 shares of common stock at a price of $0, reported as directly owned. After this transaction, he beneficially owned 29,041.522 shares of DENTSPLY SIRONA common stock.
According to the footnote, these shares represent dividends on existing restricted stock units (RSUs), credited in the form of additional RSUs. These dividend RSUs carry the same vesting terms as the underlying RSU awards, vest simultaneously with them, and each RSU converts into one share of common stock.
DENTSPLY SIRONA Inc. director Brian T. Gladden reported receiving additional equity-linked compensation. On 01/09/2026, he acquired 314.959 shares of common stock at a price of $0, reported as directly owned. After this transaction, he beneficially owned 29,041.522 shares of DENTSPLY SIRONA common stock.
According to the footnote, these shares represent dividends on existing restricted stock units (RSUs), credited in the form of additional RSUs. These dividend RSUs carry the same vesting terms as the underlying RSU awards, vest simultaneously with them, and each RSU converts into one share of common stock.